Advertisement

The Importance of Repeat Imaging Prior to Treatment Decision-making in Testicular Cancer: Commentary From the Inaugural Global Society of Rare Genitourinary Tumors Summit

Published:December 21, 2022DOI:https://doi.org/10.1016/j.clgc.2022.12.005

      Abstract

      Testicular cancer is a rare cancer that often affects young and otherwise healthy patients. Imaging plays a critical role in the staging and surveillance of patients with testicular cancer. Indeterminate findings on staging or surveillance imaging, can lead to challenging management decisions for clinicians and patients. In this article, we review the importance of short-interval, repeat imaging for several scenarios faced by patients with testicular cancer and their clinicians. The challenging scenarios and recommendations provided in this article summarize the discussion from the inaugural Global Society of Rare Genitourinary Tumors (GSRGT) Summit held on December 11-12, 2020.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. World Health Organization. Testis - Source: Globocan 2020. Published online 2020:9-10.

        • Henley SJ
        • Ward EM
        • Scott S
        • et al.
        Annual report to the nation on the status of cancer, part I: National cancer statistics.
        Cancer. 2020; 126: 2225-2249https://doi.org/10.1002/cncr.32802
        • Verdecchia A
        • Francisci S
        • Brenner H
        • et al.
        Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data.
        Lancet Oncol. 2007; (Published online)https://doi.org/10.1016/S1470-2045(07)70246-2
        • Fung C
        • Dinh PC
        • Fossa SD
        • Travis LB.
        Testicular cancer survivorship.
        JNCCN. 2019; 17: 1557-1568https://doi.org/10.6004/jnccn.2019.7369
        • de Vries G
        • Rosas-Plaza X
        • van Vugt MATM
        • Gietema JA
        • de Jong S.
        Testicular cancer: determinants of cisplatin sensitivity and novel therapeutic opportunities.
        Cancer Treatment Rev. 2020; (Published online)https://doi.org/10.1016/j.ctrv.2020.102054
        • Pierorazio PM
        • Albers P
        • Black PC
        • et al.
        Non–risk-adapted surveillance for stage I testicular cancer: critical review and summary [Figure presented].
        Eur Urol. 2018; 73: 899-907https://doi.org/10.1016/j.eururo.2017.12.030
        • Nason GJ
        • Leao R
        • Hamilton RJ.
        Active surveillance in stage 1 disease: standard of care independent of risk factors?.
        Curr Opin Urol. 2020; (Published online)https://doi.org/10.1097/MOU.0000000000000708
        • Stephenson A
        • Eggener SE
        • Bass EB
        • et al.
        Diagnosis and treatment of early stage testicular cancer: AUA guideline.
        J Urol. 2019; 202: 272-281https://doi.org/10.1097/JU.0000000000000318
        • Gilligan T
        • Lin DW
        • Aggarwal R
        • et al.
        Testicular cancer, version 2.2020.
        JNCCN J Natl Compr Cancer Netw. 2019; 17: 1529-1554https://doi.org/10.6004/jnccn.2019.0058
      2. Nauman M, Leslie SW. Nonseminomatous testicular tumors; 2021.

        • Lieng H
        • Warde P
        • Bedard P
        • et al.
        Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach.
        J Can Urol Assoc. 2018; 12: 59-66https://doi.org/10.5489/cuaj.4531
        • Gilligan T
        • Lin DW
        • Aggarwal R
        • et al.
        Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
        J Natl Comprehens Cancer Netw. 2019; (Published online)https://doi.org/10.6004/jnccn.2019.0058
        • Chakiryan NH
        • Dahmen A
        • Cucchiara V
        • et al.
        Reliability of serum tumor marker measurement to diagnose recurrence in patients with clinical stage I nonseminomatous germ cell tumors undergoing active surveillance: a systematic review.
        J Urol. 2021; (Published online)https://doi.org/10.1097/JU.0000000000001685
        • Ray B
        • Hajdu SI
        • Whitmore WF.
        Distribution of retroperitoneal lymph node metastases in testicular germinal tumors.
        Cancer. 1974; 33: 340-348https://doi.org/10.1002/1097-0142(197402)33:2<340::AID-CNCR2820330207>3.0.CO;2-Y
        • Kreydin EI
        • Barrisford GW
        • Feldman AS
        • Preston MA.
        Testicular cancer: what the radiologist needs to know.
        Am J Roentgenol. 2013; 200: 1215-1225https://doi.org/10.2214/AJR.12.10319
      3. Hilton S, Teitcher JB, Begg CB, Castehlmno RA. Germ cell cancer: size and distribution. 1997:521-525.

        • Habermann TM
        • Steensma DP.
        Lymphadenopathy.
        Mayo Clin Proc. 2000; 75: 723-732https://doi.org/10.5005/jp/books/12296_70
        • Gaddey HL
        • Riegel AM.
        Unexplained lymphadenopathy: evaluation and differential diagnosis.
        Am Fam Phys. 2016; 94: 896-903
        • Howard SA
        • Gray KP
        • O'Donnell EK
        • Fennessy FM
        • Beard CJ
        • Sweeney CJ
        Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor.
        Am J Roentgenol. 2014; (Published online)https://doi.org/10.2214/AJR.13.11615
        • Tandstad T
        • Dahl O
        • Cohn-Cedermark G
        • et al.
        Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
        J Clin Oncol. 2009; (Published online)https://doi.org/10.1200/JCO.2008.18.8953
        • EAU Guidelines
        Edn. Presented at the EAU Annual Congress, Milan2021
        • Milk N
        • Leibovitch I
        • Keizman D
        • Dresler H
        • Sternberg I.
        Is surveillance without immediate treatment an option for newly diagnosed testicular germ-cell cancer patients with borderline size retroperitoneal lymph nodes on computed tomography scan?.
        J Clin Oncol. 2018; 36: 560https://doi.org/10.1016/j.juro.2018.02.1212
        • Feldman DR.
        State-of-the-art management of germ cell tumors.
        Am Soc Clin Oncol Educ Book. 2018; (Published online)https://doi.org/10.1200/edbk_201139
        • Albers P
        • Hiester A
        • Grosse Siemer R
        • Lusch A
        The PRIMETEST trial: interim analysis of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment.
        J Clin Oncol. 2019; (Published online)https://doi.org/10.1200/jco.2019.37.7_suppl.507
        • Daneshmand S
        • Cary C
        • Masterson TA
        • et al.
        SEMS trial: result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma.
        J Clin Oncol. 2021; (Published online)https://doi.org/10.1200/jco.2021.39.6_suppl.375
        • Feldman DR
        • Bosl GJ
        • Sheinfeld J
        • Motzer RJ.
        Medical treatment of advanced testicular cancer.
        JAMA. 2008; 299: 672-684
        • Ahmed T
        • Bosl GJ
        • Hajdu SI.
        Teratoma with malignant transformation in germ cell tumors in men.
        Cancer. 1985; (Published online)https://doi.org/10.1002/1097-0142(19850815)56:4<860::AID-CNCR2820560426>3.0.CO;2-3
        • Tait D
        • Peckham MJ
        • Hendry WF
        • Goldstraw P.
        Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: The significance of histology with particular reference to differentiated (mature) teratoma.
        Br J Cancer. 1984; (Published online)https://doi.org/10.1038/bjc.1984.226
        • Wetherell D
        • Weerakoon M
        • Williams D
        • et al.
        Mature and immature teratoma: a review of pathological characteristics and treatment options.
        Med & Surg Urol. 2014; (Published online)https://doi.org/10.4172/2168-9857.1000124
        • Nason GJ
        • Jewett MAS
        • Bostrom PJ
        • et al.
        Long-term surveillance of patients with complete response following chemotherapy for metastatic nonseminomatous germ cell tumor.
        Eur Urol Oncol. 2021; (Published online)https://doi.org/10.1016/j.euo.2020.08.007
        • Ravi R
        • Ong J
        • Oliver RTD
        • Badenoch DF
        • Fowler CG
        • Hendry WF.
        The management of residual masses after chemotherapy in metastatic seminoma.
        BJU Int. 1999; (Published online)https://doi.org/10.1046/j.1464-410X.1999.00974.x
        • Treglia G
        • Sadeghi R
        • Annunziata S
        • Caldarella C
        • Bertagna F
        • Giovanella L.
        Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis.
        BioMed Res Int. 2014; (Published online)https://doi.org/10.1155/2014/852681
        • Baniel J
        • Foster RS
        • Rowland RG
        • Bihrle R
        • Donohue JP.
        Complications of post-chemotherapy retroperitoneal lymph node dissection.
        J Urol. 1995; 153 (Published online): 976-980
        • Heidenreich A
        • Pfister D
        • Witthuhn R
        • Thüer D
        • Albers P.
        Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection.
        Eur Urol. 2009; (Published online)https://doi.org/10.1016/j.eururo.2008.09.027
        • Steyerberg EW
        • Keizer HJ
        • Stoter G
        • Habbema JDF.
        Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections.
        Eur J Cancer. 1994; (Published online)https://doi.org/10.1016/0959-8049(94)90164-3
        • Napier MP
        • Naraghi A
        • Christmas TJ
        • Rustin GJS.
        Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumors.
        Br J Cancer. 2000; (Published online)https://doi.org/10.1054/bjoc.2000.1416
        • Rice K
        • Cary C
        • Masterson T
        • Foster R.
        Campbell Walsh Urology 11th Edition - Chapter 35 - Surgery of Testicular Tumors.
        Elsevier, Philedelphia, PA2016
        • Ruf CG
        • Krampe S
        • Matthies C
        • et al.
        Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature.
        World J Surg Oncol. 2020; 18: 253https://doi.org/10.1186/s12957-020-02032-1
        • Leão R
        • van Agthoven T
        • Figueiredo A
        • et al.
        Serum miRNA predicts viable disease after chemotherapy in patients with testicular nonseminoma germ cell tumor.
        J Urol. 2018; (Published online)https://doi.org/10.1016/j.juro.2018.02.068
        • Baessler B
        • Nestler T
        • Pinto dos Santos D
        • et al.
        Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection.
        Eur Radiol. 2020; 30: 2334-2345
        • Larsen SKA
        • Løgager V
        • Bylov C
        • et al.
        Can whole-body MRI replace CT in management of metastatic testicular cancer? A prospective, non-inferiority study.
        J Cancer Res Clin Oncol. 2022; (0123456789)https://doi.org/10.1007/s00432-022-03996-1
        • Joice GA
        • Rowe SP
        • Gorin MA
        • Pierorazio PM.
        Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases.
        Curr Urol Rep. 2018; (Published online)https://doi.org/10.1007/s11934-018-0863-3